CytomX Therapeutics Inc Environmental Analytics
Environmental and financial analysis dashboard for CytomX Therapeutics Inc. Industry: PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
Company Overview for CytomX Therapeutics Inc
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.74m
Operational Environmental Cost Intensity
1.38%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-0.11m
Decoupling Rate (2020-2022)
-28%
Adjusted EBITDA
$-100m
Adjusted EBITDA Margin
-187%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -9.62% | -8.44% | 108.07% | ||
| 0.29% | 0.38% | 0.45% | 0.49% | |
| -3.78% | -7.85% | 142.45% | ||
| 0.56% | 0.77% | 0.93% | 1.19% | |
| $1m | $1m | $1m | $2m | |
| -5.78% | -8.04% | 131.21% | ||
| 0.85% | 1.15% | 1.38% | 1.68% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-187%
Adjusted EBIT Margin
-192%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$100m | $70m | $53m | $101m | |
| -30.68% | -23.59% | 90.39% | ||
$215m | $281m | $152m | $106m | |
| 213.94% | 403.75% | 286.02% | 104.26% | |
$-114m | $-211m | $-99m | $-4m | |
| -113.94% | -303.75% | -186.02% | -4.26% | |
$-118m | $-216m | $-101m | $-6m | |
| -117.70% | -311.00% | -190.61% | -6.41% | |
| ENVIRONMENTAL COST DATA | ||||
$1m | $1m | $1m | $2m | |
| 0.85% | 1.15% | 1.38% | 1.68% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-115m | $-212m | $-100m | $-6m | |
| -114.79% | -304.90% | -187.40% | -5.94% | |
$-119m | $-217m | $-102m | $-8m | |
| -118.55% | -312.15% | -192.00% | -8.09% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
RESEARCH AND EXPERIMENTAL DEVELOPMENT ON NATURAL SCIENCES AND ENGINEERING
Scope 1 (% of Sales)
0.45%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.38%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
CytomX Therapeutics Inc | US | $1m | 1.38% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022